Source: Drug Delivery Leader
Similar Posts
Troy Russell’s Spinal Cord Injury Story
In August 2012, Troy Russell, a scholar athlete, broke two vertebrae in his neck in a diving accident at a Narragansett, RI beach. The break in his neck resulted in an initial loss of mobility to his legs and arms. Over time and through a lot of hard work, Troy has improved physically. Today, he…
Dignify Therapeutics welcomes leading spinal injury expert Alexander “Sasha” Rabchevsky PhD, to its Scientific Advisory Board
RESEARCH TRIANGLE PARK, NC (August 5, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, announced that Dr. Rabchevsky has joined Dignify’s Scientific Advisory Board (SAB). Dr. Rabchevsky is currently Professor of Physiology and inaugural faculty member of the Spinal Cord & Brain Injury Research Center at the University…
Dignify Therapeutics’ Chief Scientific Officer invited to participate at CURE-UAB
Dignify Therapeutics’ Chief Scientific Officer, Karl B. Thor, PhD, has been invited to participate as a Faculty member at the 2nd International Congress on Underactive Bladder – CURE-UAB in Denver, CO, Dec. 3-4, 2015. His presentation is entitled “Pharmaceutical Targets for Drug-induced Voiding”. This NIH-sponsored congress brings together academic, pharmaceutical, and medical device experts to…
Dignify Therapeutics Selected as a Praxis SCI Accelerate Company
Byjwelch
Company RESEARCH TRIANGLE PARK, NC (October 22, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program. SCI Accelerate is a commercialization program ‘geared towards healthcare companies with a product ready to launch into…
Dignify Therapeutics awarded two new research grants from the National Institutes of Health (NIH)
RESEARCH TRIANGLE PARK, NC (September 19, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, recently received two significant research grants from the NIH. These grants add to the previous $20 million in research funding the company has received to advance multiple therapeutics for bladder and bowel disorders. Grants…
Dignify Therapeutics Highlights Clinical Development Plans at the BIO CEO & Investor Conference
Byjwelch
Research Triangle Park, NC – February 14, 2025 – Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological conditions, presented its clinical development plans for its lead assets, DTI-117 and DTI-301, at the BIO CEO & Investor Conference held in New York on February 10-11, 2025. During…